Mupirocin Ointment
 Mupirocin

drug-information.ru

|Mupirocin Ointment Mupirocin

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Mupirocin

Dosage Form: Ointment

Rx only
For Dermatologic Use

Mupirocin Description

Each gram of Mupirocin ointment USP, 2% contains 20 mg Mupirocin in a bland water miscible ointment base (polyethylene glycol ointment, N.F.) consisting of polyethylene glycol 400 and polyethylene glycol 3350.

Mupirocin is a naturally occurring antibiotic. The chemical name is (E) - (2S,3R,4R,5S) - 5 - [(2S,3S,4S,5S) - 2,3 - Epoxy - 5 - hydroxy - 4 - methylhexyl]tetrahydro - 3,4 - dihydroxy - β - methyl - 2H - pyran - 2 - crotonic acid,ester with 9-hydroxynonanoic acid.

The molecular formula of Mupirocin is C26H44O9 and the molecular weight is 500.63. The chemical structure is:

Mupirocin - Clinical Pharmacology

Application of 14C-labeled Mupirocin ointment to the lower arm of normal male subjects followed by occlusion for 24 hours showed no measurable systemic absorption (<1.1 nanogram Mupirocin per milliliter of whole blood). Measurable radioactivity was present in the stratum corneum of these subjects 72 hours after application.

Following intravenous or oral administration, Mupirocin is rapidly metabolized. The principal metabolite, monic acid, is eliminated by renal excretion, and demonstrates no antibacterial activity. In a study conducted in seven healthy adult male subjects, the elimination half-life after intravenous administration of Mupirocin was 20 to 40 minutes for Mupirocin and 30 to 80 minutes for monic acid. The pharmacokinetics of Mupirocin has not been studied in individuals with renal insufficiency.

Microbiology: Mupirocin is an antibacterial agent produced by fermentation using the organism Pseudomonas fluorescens. It is active against a wide range of gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). It is also active against certain gram-negative bacteria. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this unique mode of action, Mupirocin demonstrates no in vitro cross-resistance with other classes of antimicrobial agents.

Resistance occurs rarely. However, when Mupirocin resistance does occur, it appears to result from the production of a modified isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC >1024 mcg/mL) has been reported in some strains of S. aureus and coagulase-negative staphylococci.

Mupirocin is bactericidal at concentrations achieved by topical administration. However, the minimum bactericidal concentration (MBC) against relevant pathogens is generally eight-fold to thirty-fold higher than the minimum inhibitory concentration (MIC). In addition, Mupirocin is highly protein bound (>97%), and the effect of wound secretions on the MICs of Mupirocin has not been determined.

Mupirocin has been shown to be active against most strains of Staphylococcus aureus and Streptococcus pyogenes, both in vitro and in clinical studies. (See INDICATIONS AND USAGE.) The following in vitro data are available, BUT THEIR CLINICAL SIGNIFICANCE IS UNKNOWN. Mupirocin is active against most strains of Staphylococcus epidermidis and Staphylococcus saprophyticus.

Indications and Usage for Mupirocin

Mupirocin ointment, 2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes.

Contraindications

This drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.

Warnings

Mupirocin ointment is not for ophthalmic use.

Precautions

If a reaction suggesting sensitivity or chemical irritation should occur with the use of Mupirocin ointment 2%, treatment should be discontinued and appropriate alternative therapy for the infection instituted. As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. Mupirocin ointment is not formulated for use on mucosal surfaces. Intranasal use has been associated with isolated reports of stinging and drying.

Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other polyethylene glycol-based ointments, Mupirocin ointment should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment. A paraffin-based formulation- *Bactroban® Nasal (Mupirocin calcium ointment) - is available for intranasal use.

Information for Patients: Use this medication only as directed by your healthcare practitioner. It is for external use only. Avoid contact with the eyes. The medication should be stopped and your healthcare practitioner contacted if irritation, severe itching, or rash occurs. If impetigo has not improved in 3 to 5 days, contact your healthcare practitioner.

Drug Interactions: The effect of the concurrent application of Mupirocin ointment and other drug products has not been studied.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate carcinogenic potential of Mupirocin have not been conducted. Results of the following studies performed with Mupirocin calcium or Mupirocin sodium in vitro and in vivo did not indicate a potential for genotoxicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, Salmonella reversion test (Ames), Escherichia coli mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in male and female rats with Mupirocin administered subcutaneously at doses up to 14 times a human topical dose (approximately 60 mg Mupirocin per day) on a mg/m2 basis and revealed no evidence of impaired fertility and reproductive performance from Mupirocin.

Pregnancy Teratogenic Effects.Pregnancy Category B: Reproduction studies have been performed in rats and rabbits with Mupirocin administered subcutaneously at doses up to 22 and 43 times, respectively, the human topical dose (approximately 60 mg Mupirocin per day) on a mg/m2 basis and revealed no evidence of harm to the fetus due to Mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Mupirocin ointment is administered to a nursing woman.

Pediatric Use: The safety and effectiveness of Mupirocin ointment have been established in the age range of 2 months to 16 years. Use of Mupirocin ointment in these age groups is supported by evidence from adequate and well-controlled studies of Mupirocin ointment in impetigo in pediatric patients studied as a part of the pivotal clinical trials. (See CLINICAL STUDIES.)

Adverse Reactions

The following local adverse reactions have been reported in connection with the use of Mupirocin ointment : burning, stinging, or pain in 1.5% of patients; itching in 1% of patients; rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis, and increased exudate in less than 1% of patients.

Mupirocin Dosage and Administration

A small amount of Mupirocin ointment should be applied to the affected area three times daily. The area treated may be covered with a gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.

Clinical Studies

The efficacy of topical Mupirocin ointment in impetigo was tested in two studies. In the first, patients with impetigo were randomized to receive either Mupirocin ointment or vehicle placebo t.i.d. for 8 to 12 days. Clinical efficacy rates at end of therapy in the evaluable populations (adults and pediatric patients included) were 71% for Mupirocin ointment (n=49) and 35% for vehicle placebo (n=51). Pathogen eradication rates in the evaluable populations were 94% for Mupirocin ointment and 62% for vehicle placebo. There were no side effects reported in the group receiving Mupirocin ointment. In the second study, patients with impetigo were randomized to receive either Mupirocin ointment t.i.d. or 30 to 40 mg/kg oral erythromycin ethylsuccinate per day (this was an unblinded study) for 8 days. There was a follow-up visit 1 week after treatment ended.

Clinical efficacy rates at the follow-up visit in the evaluable populations (adults and pediatric patients included) were 93% for Mupirocin ointment (n=29) and 78.5% for erythromycin (n=28). Pathogen eradication rates in the evaluable patient populations were 100% for both test groups. There were no side effects reported in the Mupirocin ointment group.

Pediatrics

There were 91 pediatric patients aged 2 months to 15 years in the first study described above. Clinical efficacy rates at end of therapy in the evaluable populations were 78% for Mupirocin ointment (n=42) and 36% for vehicle placebo (n=49). In the second study described above, all patients were pediatric except two adults in the group receiving Mupirocin ointment. The age range of the pediatric patients was 7 months to 13 years.

The clinical efficacy rate for Mupirocin ointment (n=27) was 96%, and for erythromycin it was unchanged (78.5%).

How is Mupirocin Supplied

Mupirocin Ointment USP, 2% is supplied
      NDC 0168-0352-09       72 x 0.9 gram ( 1/32 Oz) Foilpac®
      NDC 0168-0352-22       22 gram tube

Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature].

*Bactroban® Nasal is a registered trademark of SmithKline Pharmaceuticals.

E. FOUGERA & CO.
a division of Altana Inc
MELVILLE, NEW YORK 11747

I2352A/IF2352A
R8/05
#122


Mupirocin (Mupirocin)
PRODUCT INFO
Product Code 0168-0352 Dosage Form OINTMENT
Route Of Administration TOPICAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Mupirocin (Mupirocin) Active 20 MILLIGRAM  In 1 GRAM
polyethylene glycol 400 Inactive  
polyethylene glycol 3350 Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0168-0352-22 22 GRAM In 1 TUBE None
2 0168-0352-09 9 GRAM In 1 PACKET None

Revised: 02/2007





Where can I get more information about Mupirocin Ointment Mupirocin ? We recommend to use www.Drugs.com

Typical mistypes for Mupirocin Ointment Mupirocin
nupirocin ointment mupirocin, kupirocin ointment mupirocin, jupirocin ointment mupirocin, mypirocin ointment mupirocin, mhpirocin ointment mupirocin, mjpirocin ointment mupirocin, mipirocin ointment mupirocin, m8pirocin ointment mupirocin, m7pirocin ointment mupirocin, muoirocin ointment mupirocin, mulirocin ointment mupirocin, mu-irocin ointment mupirocin, mu0irocin ointment mupirocin, mupurocin ointment mupirocin, mupjrocin ointment mupirocin, mupkrocin ointment mupirocin, muporocin ointment mupirocin, mup9rocin ointment mupirocin, mup8rocin ointment mupirocin, mupieocin ointment mupirocin, mupidocin ointment mupirocin, mupifocin ointment mupirocin, mupitocin ointment mupirocin, mupi5ocin ointment mupirocin, mupi4ocin ointment mupirocin, mupiricin ointment mupirocin, mupirkcin ointment mupirocin, mupirlcin ointment mupirocin, mupirpcin ointment mupirocin, mupir0cin ointment mupirocin, mupir9cin ointment mupirocin, mupiroxin ointment mupirocin, mupirovin ointment mupirocin, mupirofin ointment mupirocin, mupirodin ointment mupirocin, mupirocun ointment mupirocin, mupirocjn ointment mupirocin, mupirockn ointment mupirocin, mupirocon ointment mupirocin, mupiroc9n ointment mupirocin, mupiroc8n ointment mupirocin, mupirocib ointment mupirocin, mupirocim ointment mupirocin, mupirocij ointment mupirocin, mupirocih ointment mupirocin, mupirocin iintment mupirocin, mupirocin kintment mupirocin, mupirocin lintment mupirocin, mupirocin pintment mupirocin, mupirocin 0intment mupirocin, mupirocin 9intment mupirocin, mupirocin ountment mupirocin, mupirocin ojntment mupirocin, mupirocin okntment mupirocin, mupirocin oontment mupirocin, mupirocin o9ntment mupirocin, mupirocin o8ntment mupirocin, mupirocin oibtment mupirocin, mupirocin oimtment mupirocin, mupirocin oijtment mupirocin, mupirocin oihtment mupirocin, mupirocin oinrment mupirocin, mupirocin oinfment mupirocin, mupirocin oingment mupirocin, mupirocin oinyment mupirocin, mupirocin oin6ment mupirocin, mupirocin oin5ment mupirocin, mupirocin ointnent mupirocin, mupirocin ointkent mupirocin, mupirocin ointjent mupirocin, mupirocin ointmwnt mupirocin, mupirocin ointmsnt mupirocin, mupirocin ointmdnt mupirocin, mupirocin ointmrnt mupirocin, mupirocin ointm4nt mupirocin, mupirocin ointm3nt mupirocin, mupirocin ointmebt mupirocin, mupirocin ointmemt mupirocin, mupirocin ointmejt mupirocin, mupirocin ointmeht mupirocin, mupirocin ointmenr mupirocin, mupirocin ointmenf mupirocin, mupirocin ointmeng mupirocin, mupirocin ointmeny mupirocin, mupirocin ointmen6 mupirocin, mupirocin ointmen5 mupirocin, mupirocin ointment nupirocin, mupirocin ointment kupirocin, mupirocin ointment jupirocin, mupirocin ointment mypirocin, mupirocin ointment mhpirocin, mupirocin ointment mjpirocin, mupirocin ointment mipirocin, mupirocin ointment m8pirocin, mupirocin ointment m7pirocin, mupirocin ointment muoirocin, mupirocin ointment mulirocin, mupirocin ointment mu-irocin, mupirocin ointment mu0irocin, mupirocin ointment mupurocin, mupirocin ointment mupjrocin, mupirocin ointment mupkrocin, mupirocin ointment muporocin, mupirocin ointment mup9rocin, mupirocin ointment mup8rocin, mupirocin ointment mupieocin, mupirocin ointment mupidocin, mupirocin ointment mupifocin, mupirocin ointment mupitocin, mupirocin ointment mupi5ocin, mupirocin ointment mupi4ocin, mupirocin ointment mupiricin, mupirocin ointment mupirkcin, mupirocin ointment mupirlcin, mupirocin ointment mupirpcin, mupirocin ointment mupir0cin, mupirocin ointment mupir9cin, mupirocin ointment mupiroxin, mupirocin ointment mupirovin, mupirocin ointment mupirofin, mupirocin ointment mupirodin, mupirocin ointment mupirocun, mupirocin ointment mupirocjn, mupirocin ointment mupirockn, mupirocin ointment mupirocon, mupirocin ointment mupiroc9n, mupirocin ointment mupiroc8n, mupirocin ointment mupirocib, mupirocin ointment mupirocim, mupirocin ointment mupirocij, mupirocin ointment mupirocih, upirocin ointment mupirocin, mpirocin ointment mupirocin, muirocin ointment mupirocin, muprocin ointment mupirocin, mupiocin ointment mupirocin, mupircin ointment mupirocin, mupiroin ointment mupirocin, mupirocn ointment mupirocin, mupiroci ointment mupirocin, mupirocinointment mupirocin, mupirocin intment mupirocin, mupirocin ontment mupirocin, mupirocin oitment mupirocin, mupirocin oinment mupirocin, mupirocin ointent mupirocin, mupirocin ointmnt mupirocin, mupirocin ointmet mupirocin, mupirocin ointmen mupirocin, mupirocin ointment mupirocin, mupirocin ointment mupirocin, mupirocin ointment upirocin, mupirocin ointment mpirocin, mupirocin ointment muirocin, mupirocin ointment muprocin, mupirocin ointment mupiocin, mupirocin ointment mupircin, mupirocin ointment mupiroin, mupirocin ointment mupirocn, mupirocin ointment mupiroci, umpirocin ointment mupirocin, mpuirocin ointment mupirocin, muiprocin ointment mupirocin, mupriocin ointment mupirocin, mupiorcin ointment mupirocin, mupircoin ointment mupirocin, mupiroicn ointment mupirocin, mupirocni ointment mupirocin, mupiroci nointment mupirocin, mupirocino intment mupirocin, mupirocin iontment mupirocin, mupirocin onitment mupirocin, mupirocin oitnment mupirocin, mupirocin oinmtent mupirocin, mupirocin ointemnt mupirocin, mupirocin ointmnet mupirocin, mupirocin ointmetn mupirocin, mupirocin ointmen t mupirocin, mupirocin ointment mupirocin, mupirocin ointment m upirocin, mupirocin ointment umpirocin, mupirocin ointment mpuirocin, mupirocin ointment muiprocin, mupirocin ointment mupriocin, mupirocin ointment mupiorcin, mupirocin ointment mupircoin, mupirocin ointment mupiroicn, mupirocin ointment mupirocni, mmupirocin ointment mupirocin, muupirocin ointment mupirocin, muppirocin ointment mupirocin, mupiirocin ointment mupirocin, mupirrocin ointment mupirocin, mupiroocin ointment mupirocin, mupiroccin ointment mupirocin, mupirociin ointment mupirocin, mupirocinn ointment mupirocin, mupirocin ointment mupirocin, mupirocin oointment mupirocin, mupirocin oiintment mupirocin, mupirocin oinntment mupirocin, mupirocin ointtment mupirocin, mupirocin ointmment mupirocin, mupirocin ointmeent mupirocin, mupirocin ointmennt mupirocin, mupirocin ointmentt mupirocin, mupirocin ointment mupirocin, mupirocin ointment mupirocin, mupirocin ointment mmupirocin, mupirocin ointment muupirocin, mupirocin ointment muppirocin, mupirocin ointment mupiirocin, mupirocin ointment mupirrocin, mupirocin ointment mupiroocin, mupirocin ointment mupiroccin, mupirocin ointment mupirociin, mupirocin ointment mupirocinn, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved